作者
Hang-Long Li, Gregory YH Lip, Qi Feng, Yue Fei, Yi-Kei Tse, Mei-Zhen Wu, Qing-Wen Ren, Hung-Fat Tse, Bernard-MY Cheung, Kai-Hang Yiu
发表日期
2021/5/7
来源
Cardiovascular Diabetology
卷号
20
期号
1
页码范围
100
出版商
BioMed Central
简介
Background
Cardiac arrhythmias are associated with poorer outcomes in patients with heart failure (HF), diabetes mellitus (DM), and chronic kidney disease (CKD). Previous studies have shown inconsistent conclusions regarding the association between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and the risk of developing arrhythmias. This study aims to investigate the association of SGLT2i treatment with arrhythmia outcomes in clinical trials of patients with HF, DM, or CKD.
Methods
MEDLINE, EMBASE, and ClinicalTrials.gov were searched from inception up to 27 August 2020. Randomized controlled trials that randomized patients with DM, CKD, or HF to SGLT2i or placebo were included. The outcomes of interest include atrial fibrillation (AF), embolic stroke, atrial flutter (AFL), AF/AFL, ventricular tachycardia (VT), and cardiac arrest. Relative risks (RRs) and 95% confidence intervals (CI) were pooled …
学术搜索中的文章
HL Li, GYH Lip, Q Feng, Y Fei, YK Tse, MZ Wu… - Cardiovascular Diabetology, 2021